Biotech booming in Belgium
Research undertaken by clinical research organisation Chiltern International into the market opportunities in Belgium, has concluded that Belgian biotechnology companies and university centres specialising in research are among the leaders in their sector, which saw turnover in Belgium rise by more than 30% during 2002. In addition, Belgium's central position within the EU has allowed the country to succeed in attracting considerable levels of investment. It is estimated that more than 100 companies in Belgium are involved with the biotechnology sector, and just under 80% of these are focused around healthcare. There are also a number of large pharmaceutical players present who have pioneered scientific research in the country. Chiltern International business development executive Dr Hannah Taylor conducted a research project into the market recently, and established links with a number of pharmaceutical and biotechnology companies, as well as visiting a variety of companies around the Brussels region. Chiltern International is a mid-sized clinical research organisation specialising in the global pharmaceutical and biotechnology industries.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds
Back to Top








